{"id":"NCT00427635","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients","officialTitle":"A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":null,"completion":"2009-04","firstPosted":"2007-01-29","resultsPosted":"2010-05-19","lastUpdate":"2010-12-20"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["GERD"],"interventions":[{"type":"DRUG","name":"Esomeprazole","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.","primaryOutcome":{"measure":"Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring","timeFrame":"Baseline and end of treatment (10-14 days)","effectByArm":[{"arm":"Esomeprazole","deltaMin":-28.01,"sd":77.7},{"arm":"Placebo","deltaMin":-24.79,"sd":44.25}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":3,"countries":["Australia","Germany","United Kingdom"]},"refs":{"pmids":["23800403"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Oxygen Saturation Decreased","Anaemia Neonatal","Constipation","Flatulence","Cyanosis"]}}